Drug intelligence / Profile preview

calcium hydroxylapatite

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Administration: Intradermal, Subcutaneous

Overview

D-Classy CaHA is a calcium hydroxylapatite (CaHA)-based dermal filler developed by Daewoong Derma & Plastic Surgery Network (DNCompany). It is an injectable medical device designed for aesthetic soft-tissue augmentation and volume restoration. The product consists of CaHA microspheres suspended in a gel carrier. Upon injection, the gel provides immediate volume correction, while the CaHA microspheres act as a scaffold to stimulate the body's natural production of collagen (neocollagenesis). This dual-action mechanism provides both immediate and long-lasting aesthetic results for the correction of facial wrinkles, folds, and contour deficiencies.

Brand names: 디클래시 CaHAD-Classy CaHA
Other names: CaHA dermal fillerCalcium hydroxylapatite dermal filler

Beyond the preview

Go deeper on calcium hydroxylapatite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcium hydroxylapatite.

Explore the full profile